Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 17
2004 11
2005 8
2006 6
2007 6
2008 7
2009 7
2010 16
2011 14
2012 10
2013 9
2014 9
2015 12
2016 8
2017 12
2018 19
2019 11
2020 10
2021 8
2022 7
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Zhu AX, et al. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Lancet Oncol. 2018. PMID: 29875066 Clinical Trial.
[Diagnosis of portal hypertension].
Naoe H, Tanaka M, Sasaki Y. Naoe H, et al. Among authors: sasaki y. Nihon Shokakibyo Gakkai Zasshi. 2019;116(5):374-385. doi: 10.11405/nisshoshi.116.374. Nihon Shokakibyo Gakkai Zasshi. 2019. PMID: 31080217 Japanese. No abstract available.
Multicenter epidemiological survey of pneumatosis intestinalis in Japan.
Ohmiya N, Hirata I, Sakamoto H, Morishita T, Saito E, Matsuoka K, Nagaya T, Nagata S, Mukae M, Sano K, Suzuki T, Tarumi KI, Shimizu S, Kawashima K, Hibi T; Intractable Diseases, the Health and Labour Sciences Research Group. Ohmiya N, et al. BMC Gastroenterol. 2022 May 31;22(1):272. doi: 10.1186/s12876-022-02343-5. BMC Gastroenterol. 2022. PMID: 35641910 Free PMC article.
Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, Li CL, Wei F, Xu Y, Imai K, Takai K, Chuma M, Komatsu N, Furutani Y, Gailhouste L, Aikata H, Chayama K, Enomoto M, Tateishi R, Kawaguchi K, Yamashita T, Kaneko S, Nagaoka K, Tanaka M, Sasaki Y, Tanaka Y, Baba H, Miura K, Ochi S, Masaki T, Kojima S, Matsuura T, Shimizu M, Chen PJ, Moriwaki H, Suzuki H. Qin XY, et al. Among authors: sasaki y. Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893. Online ahead of print. Int J Cancer. 2024. PMID: 38380807
193 results